This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “Company,” together with its subsidiaries, the “Group”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group. 

The board (the “Board”) of directors (“Directors”, and each a “Director”) of the Company is pleased to announce that the Group has submitted the application for Phase III clinical trial of IMM2510 for the treatment of immunotherapy (IO) resistant non-small cell lung cancer (NSCLC) and has recently submitted two Phase III clinical trials targeting different lung cancer to the Center for Drug Evaluation of National Medical Products Administration of the People’s Republic of China (the “NMPA”). 

Data from the Phase I study presented at the 2025 World Conference on Lung Cancer (the “WCLC”) has recently showed that IMM2510 achieved an objective response rate (ORR) of 35.3% and a disease control rate (DCR) of 76.5% (13/17) in 17 evaluable patients with advanced squamous NSCLC (SQ-NSCLC) who had previously received immune therapy. The median duration of response (DoR) was 7.59 months (95% CI: 4.07 -NA), and the median progression-free survival (PFS) was 9.4 months (95% CI: 1.87 -NA). Based on these results, the Company plans to further verify the efficacy and safety of IMM2510 in Phase III clinical trials, with the aim of providing a more effective treatment option for patients with lung cancer.